Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging

Adin, Mehmet Emin; Isufi, Edvin; Kulon, Michal; Pucar, Darko

doi:10.1001/jamaoncol.2021.1794

Cited by 48 publications

(56 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike the literature [6], in our data, HLN detection rate was not influenced by oncological status, particularly by hematological disease and immunosuppressive/immunotherapy. In addition, differently from Adin et al, who observed a more common HLN detection rate after the Moderna vaccine (57%) than the Pfizer (15%) vaccine [9], the type of vaccination did not significantly impact on HLN detection; probably linked to the higher proportion (87%) of patients who received Pfizer vaccine in our sample.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management

Ferrari

Nappi

Santo

et al. 2021

Cancers

View full text Add to dashboard Cite

The widespread COVID-19 vaccination led to unexpected PET findings. Notably, axillary and interpectoral lymphadenopathies ipsilateral to the vaccine inoculation were observed. We aimed to assess the hypermetabolic lymphadenopathy (HLN) detection rate on PET/CT. Secondly, we investigated factors that might help in HLN differential diagnosis. A retrospective analysis on 1196 consecutive patients referred for a PET/CT was performed. All patients were asked about the date, type and site of vaccine injections. HLNs were recorded and categorized according to risk classes and SUVmax grades. A statistical analysis was performed to assess the correlation between HLN detection and different clinical/vaccine data. HLN detection rate was 15% and 27% in the No Vac- and vac-groups (p < 0.001), respectively. In the Vac-group, age (p < 0.001) and time interval from vaccine-to-PET (p = 0.010) were inversely correlated with HLN detection. Furthermore, SUVmax significantly changed during time intervals, with lower values beyond 20 days (p < 0.001). In the era of mass COVID-19 vaccination, a higher axillary and interpectoral lymphadenopathies detection ipsilateral to vaccine injection was observed. These PET findings can be wrongly interpreted, complicating cancer patients’ management. To minimize these pitfalls, a detailed vaccination anamnesis must be recorded and should take into account the appropriate PET schedule.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…Since mass COVID-19 vaccination started, several evidences of PET/CT findings have emerged in literature, which mainly consisted in clinical case reports [6][7][8][9][10].…”

Section: Discussionmentioning

confidence: 99%

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management

Ferrari

Nappi

Santo

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Among the 728 vaccinated patients who underwent PET-CT scans in the aforementioned study, 113 (15.5%) were breast cancer patients [ 28 ]. A recently published study from the US (although with limited sample size and follow-up) also found that women might be more likely to develop reactive nodes following COVID-19 vaccination, with 7 out of 9 (78%) patients with lymphadenopathy (in a cohort of 68 vaccinated patients undergoing PET-CT scan for oncological indications) being female [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care

Garreffa

Hamad

O’Sullivan

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

Purpose Over 1 billion doses of COVID-19 vaccines have been already administered across the US, the UK and the EU at the time of writing. Furthermore, 1.82 million of booster doses have been administered in the US since 13 th August, and similar booster programmes are currently planned or under consideration in the UK and the EU beginning in the autumn of 2021. Early reports showed an association between vaccine administration and the development of ipsilateral axillary and supraclavicular lymphadenopathy which could interfere with the diagnosis, treatment and follow-up of breast cancer patients. In this paper, we review the available evidence on vaccine-related lymphadenopathy, and we discuss the clinical implications of same on breast cancer diagnosis and management. Methods A literature search was performed - PubMed, Ovid Medline, Scopus, CINHAL, Springer Nature, Sciencedirect, Academic Search Premiere and the Directory of Open Access Journals were searched for articles reporting on regional palpable or image-detected lymphadenopathy following COVID-19 vaccination. Separately, we compiled a series of case studies from the University Hospitals of Derby and Burton, UK and the Mayo Clinic in Minnesota, USA to illustrate the impact that regional lymphadenopathy post-COVID-19 vaccination can have on the diagnosis and management of patients being seen in diagnostic and therapeutic breast clinics. Results From the literature search 15 studies met the inclusion criteria (n = 2057 patients, 737 with lymphadenopathy). The incidence of lymphadenopathy ranged between 14.5% and 53% and persisted for >6 weeks in 29% of patients. Conclusions Clinicians managing breast cancer patients should be aware that the COVID-19 vaccination may result in regional lymphadenopathy in a significant number of patients which can result in unnecessary investigations, treatment and increased patient anxiety. An accurate COVID-19 vaccination history should be collected from all patients where regional lymphadenopathy is a clinical &/or an imaging finding and then combined with clinical judgment when managing individual cases.

show abstract

“…The most common adverse reactions include pain at the injection site, headache, fatigue, myalgia, fever, and joint pain [2] . Less common side effects include lymphadenopathy or lymphadenitis in the ipsilateral axillary region [3] . Additionally, reactivation of the Gammaherpesvirinae subfamily, such as Epstein-Barr virus (EBV), and herpesvirus have been reported in case studies [4] , [5] , [6] .…”

Section: Introductionmentioning

confidence: 99%

A Case Report of Posttransplant Lymphoproliferative Disorder After AstraZeneca Coronavirus Disease 2019 Vaccine in a Heart Transplant Recipient

Tang

Hsu

Lee

et al. 2022

Transplantation Proceedings

View full text Add to dashboard Cite

We report a case of a heart transplant recipient who presented with a rapidly growing Epstein-Barr virus (EBV)-positive, diffuse large B-cell lymphoma seven days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Because of the atypical radiological presentation, the initial tentative diagnosis was a mediastinal abscess. This observation indicates a potential risk of EBV reactivation after COVID-19 vaccination, which might lead to or aggravate the presentation of post-transplant lymphoproliferative disorder in transplantation patients. Transplant surgeons should be aware of the potential immunomodulatory effects of COVID-19 vaccination.

show abstract

Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging

Cited by 48 publications

References 4 publications

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management

The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care

A Case Report of Posttransplant Lymphoproliferative Disorder After AstraZeneca Coronavirus Disease 2019 Vaccine in a Heart Transplant Recipient

Contact Info

Product

Resources

About